ECOS-300CY
Use with Ex Vivo Organ Perfusion (EVOP) to manage inflammatory processes in donor organs
Device DevelopmentNot authorized/approved in the US
Key Facts
Indication
Use with Ex Vivo Organ Perfusion (EVOP) to manage inflammatory processes in donor organs
Phase
Device Development
Status
Not authorized/approved in the US
Company
About CytoSorbents
CytoSorbents is a public company (NASDAQ: CTSO) pioneering blood purification to treat life-threatening conditions in intensive care and cardiac surgery. Its core technology uses highly porous polymer beads to adsorb harmful substances from blood, complementing conventional dialysis. While CytoSorb® is commercially available in over 75 countries with a CE mark, the company is actively pursuing FDA approval for its devices in the United States, representing a significant future growth opportunity.
View full company profile